Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
48
NCT04642937
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 1, 2020
Completion: Nov 30, 2024
NCT06305910
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
Start: Mar 15, 2024
Completion: Jan 15, 2027